Filana Therapeutics (FLNA) Free Cash Flow (2010 - 2026)

Filana Therapeutics has reported Free Cash Flow for 17 years, with the latest figure at -$3.8 million in Q2 2026.

• On a quarterly basis, Free Cash Flow rose 22.78% year-over-year to -$3.8 million in Q2 2026; TTM through Jun 2026 was -$29.3 million, a 69.43% increase from a year earlier, with the FY2025 full-year figure at -$32.9 million, up 71.9% from the prior year.
• Free Cash Flow was -$3.8 million for Q2 2026 at Filana Therapeutics, up from -$8.9 million in the prior quarter.
• The five-year high for Free Cash Flow was -$3.8 million in Q2 2026, with the low at -$61.3 million in Q4 2024.
• Average Free Cash Flow over 5 years is -$18.1 million, with a median of -$18.3 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2025: Free Cash Flow plunged 938.81% in 2022, then jumped 83.2% in 2025.
• Over 5 years, Free Cash Flow stood at -$21.0 million in 2022, then dropped by 6.54% to -$22.4 million in 2023, then slumped by 174.12% to -$61.3 million in 2024, then surged by 83.2% to -$10.3 million in 2025, then jumped by 62.78% to -$3.8 million in 2026.
• The last three Free Cash Flow figures came in at -$3.8 million (Q2 2026), -$8.9 million (Q1 2026), and -$10.3 million (Q4 2025), per Business Quant data.